Monday, 21 September 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

BIOSENIC Stock Falls By 34% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of BIOSENIC (BEL 20: BIOS.BR) slid by a staggering 34.02% in 21 sessions from €0.14 to €0.09 at 14:07 EST on Wednesday, following the last session's upward trend. BEL 20 is rising 0.26% to €3,770.22, following the last session's downward trend.

About BIOSENIC

BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures. The company is based in Mont-Saint-Guibert, Belgium.

Earnings Per Share

As for profitability, BIOSENIC has a trailing twelve months EPS of €-0.29.

Volatility

BIOSENIC's last week, last month's, and last quarter's current intraday variation average was a negative 5.01%, a negative 2.97%, and a positive 5.94%.

BIOSENIC's highest amplitude of average volatility was 6.35% (last week), 3.96% (last month), and 5.94% (last quarter).

More news about BIOSENIC (BIOS.BR).

Categories

stockMarket

Tags

BIOS.BRStock PricePrice DownBIOSENICMarket Session NowStock Price DownStock Market NowMarket SessionStock MarketStock
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Frontier AI Slowdown Call Splits Industry, Rattles Capex-Sensitive Markets
Anthropic's Dario Amodei publicly called for a coordinated global slowdown in frontier AI development, a stance Microsoft echoed with a 'humanist' AI code of conduct, but Nvidia and Meta's CEOs rejected any coordinated pause days later, exposing a widening rift between safety-focused and growth-focused AI leaders. The dispute landed amid growing financial scrutiny of AI infrastructure spending — a hyperscaler capex analysis, FTC warnings against antitrust waivers for AI firms, and an 8.6% single-day stock drop in GE Vernova tied directly to the slowdown remarks — signaling investors are newly nervous about whether the AI capex boom (including Alphabet's projected $701B revenue narrative) can be justified if the pace of development itself becomes contested.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,983
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,983 facts checked against source5,304 source documents archived
Query this data → isubstrate.com